ProNAi Initiates ‘Brighton’ Phase II Trial of PNT2258 in Patients with Richter’s Transformation

VANCOUVER, Oct. 29, 2015 /CNW/ – ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform, today announced it has enrolled the first patient […]

Read On ›

Concerto opening additional clinics for Medicare-Medicaid patients in Detroit

Concerto Healthcare Inc., an Irvine, Calif.-based health care company, is opening its fourth metro Detroit clinic in western Detroit on Oct. 22 to serve the Medicare-Medicaid dual-eligible population in a pilot program overseen by the Michigan […]

Read On ›

Delphinus Raises Over $39 Million in Capital

PLYMOUTH TOWNSHIP, Mich. – Sept.10, 2015 – Delphinus Medical Technologies, Inc., the leader in advanced breast ultrasound technology, announced today that it has secured an unprecedented venture round of $39.5 million. The venture capital funding […]

Read On ›

ProNAi Therapeutics Announces Closing of IPO and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

VANCOUVER, July 21, 2015 /CNW/ – ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform, today announced the closing of its initial public […]

Read On ›

ProNAi Therapeutics Announces Pricing of Initial Public Offering

VANCOUVER, July 15, 2015 /CNW/ – ProNAi Therapeutics, Inc., a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform, today announced the pricing of its initial public offering […]

Read On ›

NEOCHORD SECURES $20 MILLION SERIES C FINANCING

EDEN PRAIRIE, MN, June 9, 2015—NeoChord Inc. – a medical technology company, announced today it has closed an oversubscribed $20 million Series C financing round led by Deerfield Management, with participation from Baird Capital’s Venture […]

Read On ›

Metabolic Solutions Development Company Highlights Plans for MSDC-0602 in NASH and Polycystic Kidney Disease

 KALAMAZOO, Mich., March 18, 2015 – Metabolic Solutions Development Company (MSDC), an emerging biopharmaceutical company developing first in class therapeutics to treat diseases associated with metabolic dysfunction, today announced that Stephen Benoit, CEO, will present […]

Read On ›

ProNAi to Present at the 33rd Annual J.P. Morgan Healthcare Conference

 Vancouver, BC and Plymouth, MI – January 12, 2015. ProNAi Therapeutics Inc., a private hematology/oncology company dedicated to developing and commercializing a new class of therapeutics based on its proprietary DNAi® platform, today announced that […]

Read On ›